In MRSA bacteremia, adding a β-lactam to usual care did not improve a composite outcome at 90 days

Ann Intern Med. 2020 Jun 16;172(12):JC67. doi: 10.7326/ACPJ202006160-067.

Abstract

Tong SY, Lye DC, Yahav D, et al. Effect of vancomycin or daptomycin with vs without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. JAMA. 2020;323:527-37. 32044943.

Publication types

  • Comment

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia* / drug therapy
  • Daptomycin* / therapeutic use
  • Humans
  • Methicillin-Resistant Staphylococcus aureus*
  • Recurrence
  • Staphylococcal Infections* / drug therapy
  • Treatment Failure
  • Treatment Outcome
  • Vancomycin / therapeutic use
  • beta-Lactams / therapeutic use

Substances

  • Anti-Bacterial Agents
  • beta-Lactams
  • Vancomycin
  • Daptomycin